Casi Pharmaceuticals falls after FDA puts experimental antibody drug on hold

CASI Pharmaceuticals

26/12/2024 14:23

** Casi Pharmaceuticals'  CASI.O  shares fall 14.89% to
$2.40 premarket
    ** Co says its application to start trials for its
experimental antibody in patients with a type of complication
related to kidney transplants was placed on clinical hold
    ** The complication, known as Antibody Mediated Rejection,
occurs after a transplant when the recipient's immune system
produces antibodies that attack the transplanted organ
    ** Co's application supporting early-to-mid stage trial of
the antibody in adults with chronic immune thrombocytopenia, a
rare autoimmune blood disorder, remains open
    ** Up to last close, stock down ~60% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))